Theravance Biopharma (TBPH) Income Statement: Revenue & Earnings

Theravance Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Theravance Biopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	64.38	57.42	51.35	55.31	71.86
Cost of Revenue	37.64	40.62	63.39	193.66	260.95
Gross Profit	26.74	16.80	-12.05	-138.35	-189.10
Operating Expenses
Research & Development	37.64	40.62	63.39	193.66	0.00
Selling, General & Administrative	69.17	70.10	67.07	99.30	108.53
Operating Expenses	69.17	70.45	67.07	292.95	108.53
Operating Income	-42.44	-53.65	-79.12	-237.64	-297.63
Other Income/Expense
Interest Income	4.98	9.02	6.74	1.11	4.74
Interest Expense	-2.55	-2.35	-6.37	8.55	-8.55
Other Income/Expense	2.34	-2.74	-15.87	-20.14	-1.61
Income
Income Before Tax	-44.61	-49.27	-92.82	-265.22	-303.34
Income Tax Expense	11.80	5.92	0.01	-0.15	-8.52
Net Income	-56.42	-55.19	872.13	-199.43	-278.02
Net Income - Continuous Operations	-56.42	-55.19	-92.82	-265.07	0.00
Net Income - Discontinued Operations	0.00	0.00	964.96	65.65	0.00
EBITDA	-40.73	-51.65	-76.08	-248.08	-294.00
EBIT	-42.44	-53.65	-79.12	-256.68	-297.63
Depreciation & Amortization	1.71	2.00	3.04	8.60	3.63
Earnings Per Share
Basic EPS	-1.00	-1.00	12.00	-3.00	-4.00
Diluted EPS	-1.00	-1.00	12.00	-3.00	-4.00
Basic Shares Outstanding	48.85	55.30	73.59	69.46	62.35
Diluted Shares Outstanding	48.85	55.30	73.59	69.46	62.35